Study opens new avenue for treating ulcerative colitis or Crohn's disease

NewsGuard 100/100 Score

An international study led by the Complutense University of Madrid (UCM) and the National Centre for Cardiovascular Research (CNIC) has found that Lactobacillus bacteria present in the intestinal microbiota interact with immune system cells to strengthen the intestinal barrier.

Conducted on mice and published in Immunity, the study opens a new avenue for the treatment of diseases such as ulcerative colitis or Crohn's disease, in which the intestinal barrier becomes so weakened that bacteria can migrate to other organs, causing inflammatory processes.

Until now, only a few descriptions have existed of specific commensals in mouse microbiota that stimulate the immune system and regulate the lymphocyte population, which helps ensure that bacteria remain in the niche where they are beneficial.

"Our research shows that there are molecular patterns present in or secreted by commensal intestinal bacteria which are recognised by a receptor in the immune system cell called Mincle", reported El Salvador Iborra, a researcher in the Department of Immunology, Ophthalmology and ENT at the UCM.

This interaction between Mincle and beneficial Lactobacillus bacteria occurs in regions of the small intestine called Peyer's patches and promotes a beneficial response in the host.

A reduction in lymphocytes leads to a weakened barrier

To carry out the study, the researchers used Mincle-deficient mice, or mice deficient in one of the proteins involved in intracellular signalling of this receptor, called Syk.

The researchers found that this deficiency led to a failure to produce the instructions necessary to generate the intestinal lymphocytes essential for regulating the intestinal immune barrier function.

"We found that as a result of this reduction in the lymphocyte population, intestinal barrier function deteriorated, leading to an increase in the number of bacteria capable of migrating from the intestine and reaching the liver, generating hepatic inflammation and metabolic changes", Iborra explained.

The results of this study open a new avenue for treating disease, such as "the administration of beneficial probiotic microorganisms capable of interacting with this receptor, or prebiotics capable of promoting the growth of these intestinal bacteria", noted the UCM researcher. Iborra also added another possibility: treatment with synthetic compounds capable of binding to Mincle and triggering the beneficial response mediated by this receptor.

In addition to inflammatory bowel diseases, stress, poor diet or overuse of drugs can also weaken the intestinal barrier.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Australian scientists explore how harmful bacteria contribute to Alzheimer's